Awakn Life Sciences Company Description
Awakn Life Sciences Corp., a biotechnology company, engages in the research, development, operation, and delivery of psychedelic therapeutics to treat addiction and other mental health conditions in North America and Europe.
It develops AWKN-001, a novel medication-assisted treatments (MAT) consisting of racemic ketamine, delivered intravenously, and manualized relapse prevention cognitive behavioural therapy (CBT) which is in phase 3 trials to treat severe Alcohol Use Disorder (AUD); AWKN-002, a novel MAT consisting of a patent pending proprietary S–ketamine oral thin film, and manualized relapse prevention CBT to treat AUD; and MDMA/Zydis, an investigational medicinal product entactogen that acts as a releaser and reuptake inhibitor of serotonin, norepinephrine, and dopamine.
The company has a collaboration agreement with the University of Exeter for exploring the use of ketamine-assisted therapy to treat Severe AUD; with Graft Polymer (UK) PLC to develop chemical entity series programme for trauma-related mental health disorders; and with the University of Nottingham focusing on evaluating the company’s lead aminoindane series and its potential to enhance social cognition and pro-social behaviors.
Awakn Life Sciences Corp. is headquartered in Toronto, Canada.
| Country | Canada |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Anthony Tennyson |
Contact Details
Address: 217 Queen Street West Toronto, British Columbia M5V 0R2 Canada | |
| Website | awaknlifesciences.com |
Stock Details
| Ticker Symbol | AWKNF |
| Exchange | OTCMKTS |
| Fiscal Year | February - January |
| Reporting Currency | CAD |
| ISIN Number | CA05455W1086 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Anthony Tennyson | Co-founder, President, Chief Executive Officer and Director |
| George Scorsis | Co-founder and Chairman of the Board |
| Jonathan James Held C.A., CPA, CA | Co-founder, Chief Financial Officer, Chief Business Officer and Secretary |
| Prof. David John Nutt DM, FMedSci, FRCP, FRCPsych, FSB, Ph.D. | Chair of Pre-Clinical and Clinical Advisory Board and Chief Research Officer |